---
title: "Fortrea Holdings Inc. (FTRE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FTRE.US.md"
symbol: "FTRE.US"
name: "Fortrea Holdings Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T02:59:40.435Z"
locales:
  - [en](https://longbridge.com/en/quote/FTRE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FTRE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FTRE.US.md)
---

# Fortrea Holdings Inc. (FTRE.US)

## Company Overview

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.fortrea.com](https://www.fortrea.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.63)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 44 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.86% |  |
| Net Profit YoY | 43.46% |  |
| P/B Ratio | 2.44 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1285614000.00 |  |
| Revenue | 2708600000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -64.55% | E |
| Profit Margin | -16.50% | D |
| Gross Margin | 19.42% | D |
| Revenue YoY | 0.86% | C |
| Net Profit YoY | 43.46% | B |
| Total Assets YoY | -14.02% | E |
| Net Assets YoY | -38.76% | E |
| Cash Flow Margin | -49.38% | E |
| OCF YoY | 0.86% | C |
| Turnover | 0.93 | A |
| Gearing Ratio | 80.40% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Fortrea Holdings Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "43.46%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.44",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1285614000.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2708600000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-64.55%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-16.50%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "19.42%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "0.86%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "43.46%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-14.02%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-38.76%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-49.38%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.86%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.93",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "80.40%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.90 | 36/59 | - | - | - |
| PB | 2.47 | 26/59 | 2.37 | 1.59 | 0.68 |
| PS (TTM) | 0.48 | 5/59 | 0.49 | 0.34 | 0.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 42% |
| Hold | 6 | 50% |
| Underweight | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.71 |
| Highest Target | 20.00 |
| Lowest Target | 9.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FTRE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FTRE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/FTRE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FTRE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**